Ares Genetics ARESid and ARESiss Express Services
Ares Genetics, a subsidiary of precision medicine company OpGen, is commercially launching global genome sequencing and analysis services, ARESid and ARESiss Express. According to the company, semi-quantitative ARESid enables "accurate and comprehensive" detection and surveillance of bacterial and fungal microbes in a culture-free fashion directly from native patient specimen or environmental samples. ARESiss Express reports include outbreak-relevant information as well as actionable information on antimicrobial resistance pathogens. Sequencing results from both services are accessible to customers via AREScloud, a web application for which the company plans to release a number of new features over the coming months, the company said. Customers can submit orders for both services, which are for research use only, to be performed at Ares Genetics' service laboratory in Vienna, Austria, while US-based sequencing services will be launched later this year.